Skip to main content
. 2023 Jan 25;37(6):957–966. doi: 10.1097/QAD.0000000000003494

Fig. 2.

Forest plots for synthesized effect sizes within the efficacy studies.

Fig. 2

The figure comprises four forest plots containing results from the random effects meta-analyses conducted among efficacy studies for four primary outcomes: HIV infection (Panel a), any adverse event grade 2 or higher (Panel b), any serious adverse event (Panel c), and integrase strand transfer inhibitor (INSTI) drug resistance (Panel d). Panel a shows the relative risk of HIV acquisition comparing CAB-LA to oral PrEP arms was 0.21 (95% CI: 0.07–0.61). Panel b shows the relative risk of experiencing any adverse event grade 2 or higher comparing CAB-LA to oral PrEP arms was 1.0 (95% CI: 0.98–1.01). Panel c shows the relative risk of experiencing any serious adverse event comparing CAB-LA to oral PrEP arms was 0.99 (95% CI: 0.79–1.23). Panel d shows the relative risk of having INSTI-resistance among HIV infections identified during the trials, comparing CAB-LA to oral PrEP arms, was 20.90 (95% CI: 2.19- 199.74). CAB-LA, long-acting injectable cabotegravir; CI, confidence interval; PrEP, preexposure prophylaxis.